Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
基本信息
- 批准号:10701046
- 负责人:
- 金额:$ 69.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-06 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AnxietyBehavior TherapyBinge EatingBody CompositionBody Weight decreasedClinical ManagementCounselingDesire for foodDietDiet therapyDietary InterventionDoseDouble-Blind MethodDual-Energy X-Ray AbsorptiometryEating BehaviorEligibility DeterminationEnergy IntakeEquilibriumExercise TherapyHealth Care CostsHeart RateImpairmentIntakeKnowledgeLeptinLife StyleLifestyle TherapyLipidsMethodsMorbid ObesityOutcomePatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacotherapyPhenterminePhysical activityPlacebosPublishingQuality of lifeQuestionnairesRandomizedRandomized, Controlled TrialsSafetySequential Multiple Assignment Randomized TrialTestingTherapeuticTherapeutic EffectThyroid HormonesWeightWeight maintenance regimenWell in selfadaptive interventionbariatric surgeryclinical practicecomorbiditydepressive symptomsdesigndietarydoubly-labeled watereffective therapyefficacy evaluationenergy balanceexercise interventionexperiencefollow-upinflammatory markerloss of control over eatingnovelplacebo groupresponserestrainttopiramatetotal energy expendituretrial design
项目摘要
Project Summary
Although bariatric surgery is the most effective treatment for severe obesity, a large proportion of patients
experience significant weight regain with longer follow-up. Because weight regain is associated with re-
emergence of weight-related comorbidities, increased health care costs, and impaired quality of life, it is
imperative to effectively manage this problem. Diet, exercise, and behavior therapy have demonstrated
minimal efficacy in reversing weight regain. Pharmacotherapy could be useful to manage this clinical problem.
However, there are no published randomized controlled trials (RCTs) of pharmacotherapy for reversal of
weight regain. This is a major therapeutic gap, which the proposed project will aim to fill. In this well-powered
meticulously designed double-blind RCT employing a Sequential Multiple Assignment Randomized Trial
(SMART) design, a total of 120 subjects with weight regain after bariatric surgery, will be initially randomized in
a 3:3:2 ratio to daily treatment with topiramate (TPM) 50 mg or phentermine (PHEN) 7.5 mg or placebo. After 4
months, responders (those with ≥5% weight loss) will continue the same treatment, while nonresponders will
be re-randomized to a higher dose of the same drug or phentermine/topiramate 7.5/50 mg combination
(PHEN/TPM) during Months 5-12. The placebo group will receive placebo for the full 12 months. All subjects
will receive diet and lifestyle counseling throughout the study. Aim 1. To determine whether pharmacotherapy
can reverse post-bariatric surgery weight regain. We hypothesize that, compared to placebo, all three active
drug therapies – TPM, PHEN, and PHEN/TPM will lead to greater percent weight loss at Month 12. Aim 2. To
examine change in energy intake objectively assessed with the Intake-Balance Method using doubly labeled
water and DXA. We hypothesize that active drug therapy will lead to greater reduction in energy intake at
Month 12. Aim 3. To examine changes in the most common maladaptive eating behaviors in the post-bariatric
surgery patients - grazing, loss-of-control eating, and binge eating. We hypothesize that, compared to placebo,
all three drug therapies will lead to decreased maladaptive eating behaviors. A battery of carefully chosen
exploratory outcomes including other likely modulators of changes in energy balance (appetite, night eating
behavior, dietary restraint, thyroid hormones, leptin, and physical activity), additional efficacy (ALT, AST,
glycemia, lipid levels, inflammatory markers, quality of life, and psychological wellbeing), and safety (heart rate,
BP, anxiety, depressive symptoms) will be investigated. Additional efficacy questions including the best initial
treatment, dose escalation vs combination strategy, and each adaptive intervention will be examined. The
findings of this highly rigorous study will provide high-quality evidence for the efficacy and safety of
pharmacotherapy in reversing weight regain after bariatric surgery. Study results could lead to a change in
clinical practice paradigms and enhance long-term outcomes for patients after bariatric surgery. Because the
SMART design mimics clinical practice, the findings of this RCT are directly translatable to clinical practice.
项目摘要
虽然减肥手术是治疗严重肥胖症最有效的方法,但很大一部分患者
随着随访时间的延长,体重明显反弹。因为体重反弹与再-
出现体重相关的合并症,增加医疗保健费用,降低生活质量,
必须有效地解决这个问题。饮食锻炼和行为疗法已经证明
逆转体重反弹的效果微乎其微。药物治疗可能有助于解决这一临床问题。
然而,目前还没有发表的关于药物治疗逆转
体重恢复这是一个主要的治疗空白,拟议的项目将致力于填补这一空白。在这个强大的
采用序贯多分配随机试验精心设计的双盲随机对照试验
(SMART)设计,共120例减肥手术后体重恢复的受试者,最初将随机分配至
托吡酯(TPM)50 mg或芬特明(PHEN)7.5 mg或安慰剂的每日治疗比例为3:3:2。经过4
月,应答者(体重减轻≥5%的患者)将继续相同的治疗,而无应答者将
被重新随机分配至更高剂量的相同药物或芬特明/托吡酯7.5/50 mg组合
(PHEN/TPM)。安慰剂组将接受安慰剂治疗整整12个月。所有受试者
将在整个研究期间接受饮食和生活方式咨询。目标1。为了确定药物治疗是否
可以逆转减肥手术后的体重反弹。我们假设,与安慰剂相比,
药物治疗- TPM、PHEN和PHEN/TPM在第12个月时将导致更大的体重减轻百分比。目标2.到
使用双标记的摄入平衡法客观评估能量摄入的变化
水和DXA。我们假设,积极的药物治疗将导致更大的减少能量摄入,
第12个月。目标3.为了检查肥胖后最常见的适应不良饮食行为的变化,
手术病人--吃草、饮食失控和暴食。我们假设,与安慰剂相比,
所有这三种药物疗法都将导致适应不良饮食行为的减少。一组精心挑选的
探索性结果,包括能量平衡变化的其他可能调节剂(食欲、夜间进食
行为、饮食限制、甲状腺激素、瘦素和体力活动),额外的功效(ALT,AST,
血脂水平、炎症标志物、生活质量和心理健康)和安全性(心率,
血压、焦虑、抑郁症状)。其他疗效问题,包括最佳初始
将检查治疗、剂量递增与联合策略以及每种适应性干预。的
这项高度严格的研究的结果将为有效性和安全性提供高质量的证据。
药物治疗逆转减肥手术后体重反弹。研究结果可能会导致
临床实践范例,并提高减肥手术后患者的长期结局。因为
SMART设计模拟临床实践,该RCT的结果可直接转化为临床实践。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Weight Regain After Bariatric Surgery: Scope of the Problem, Causes, Prevention, and Treatment.
- DOI:10.1007/s11892-023-01498-z
- 发表时间:2023-03
- 期刊:
- 影响因子:4.2
- 作者:Noria, Sabrena F.;Shelby, Rita D.;Atkins, Katelyn D.;Nguyen, Ninh T.;Gadde, Kishore M.
- 通讯作者:Gadde, Kishore M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KISHORE M GADDE其他文献
KISHORE M GADDE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KISHORE M GADDE', 18)}}的其他基金
Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
- 批准号:
10678557 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别:
Pharmacotherapy in conjunction with lifestyle counseling for management of weight regain after bariatric surgery (PROJECT-BARI)
药物治疗与生活方式咨询相结合,用于控制减肥手术后的体重恢复(PROJECT-BARI)
- 批准号:
10280812 - 财政年份:2021
- 资助金额:
$ 69.29万 - 项目类别:
相似海外基金
Digital cognitive-behavior therapy for anxiety and depressive disorders: Building an impactful research project from international partnerships and knowledge exchange in primary care
针对焦虑和抑郁症的数字认知行为疗法:通过初级保健领域的国际合作和知识交流建立一个有影响力的研究项目
- 批准号:
480808 - 财政年份:2023
- 资助金额:
$ 69.29万 - 项目类别:
Miscellaneous Programs
Function of cost bias and effect of cognitive behavior therapy on social anxiety in children and adolescents
成本偏差的作用及认知行为治疗对儿童青少年社交焦虑的影响
- 批准号:
23K02970 - 财政年份:2023
- 资助金额:
$ 69.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Combined Dialectical Behavior Therapy and Digital Cognitive Behavioral Therapy for Insomnia for Adolescents at High Risk for Suicide: A Pilot RCT
辩证行为疗法和数字认知行为疗法相结合治疗自杀高危青少年的失眠:一项试点随机对照试验
- 批准号:
10643478 - 财政年份:2023
- 资助金额:
$ 69.29万 - 项目类别:
A Randomized Clinical Trial Comparing Transdiagnostic Behavior Therapy to Disorder-Specific Psychotherapy in the Recovery of Veterans with Social Anxiety Disorder and Comorbid PTSD Symptomatology
一项随机临床试验,比较跨诊断行为疗法与特定障碍心理疗法在患有社交焦虑症和共病 PTSD 症状的退伍军人康复中的作用
- 批准号:
10746930 - 财政年份:2023
- 资助金额:
$ 69.29万 - 项目类别:
Reducing suicide risk among aging caregivers of persons with AD/ADRD: Adapting, implementing, and evaluating Dialectical Behavior Therapy skills training interventions.
降低 AD/ADRD 患者老年护理人员的自杀风险:调整、实施和评估辩证行为治疗技能培训干预措施。
- 批准号:
10730708 - 财政年份:2023
- 资助金额:
$ 69.29万 - 项目类别:
A Randomized control trial of behavior therapy of tics in Japan. Exploring the behavior model of tics.
日本抽动行为治疗的随机对照试验。
- 批准号:
22K13840 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The Role of Behavior Therapy Combined with Buprenorphine for the Treatment of Opioid Use Disorder
行为疗法联合丁丙诺啡治疗阿片类药物使用障碍的作用
- 批准号:
10440820 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
- 批准号:
10429841 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效
- 批准号:
10656415 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别:
Efficacy of digital cognitive behavior therapy for insomnia for the prevention of perinatal depression - supplement
数字认知行为疗法治疗失眠预防围产期抑郁症的疗效 - 补充
- 批准号:
10794868 - 财政年份:2022
- 资助金额:
$ 69.29万 - 项目类别: